Kristie L. Kahl

With various FDA approvals in the last year alone, nurses must stay up-to-date on the changing treatment landscape of breast cancer to properly treat these patients.

A pediatric oncology nurse’s experience came full circle following her own bladder cancer diagnosis, followed by serving as a caregiver to her husband who faced the same disease 6 years later.

With a goal of championing the value of patient navigators, Susan G. Komen Greater New York City and NYU Langone have teamed up to provide patients with improved care in Brooklyn through a new patient navigation project.

The treatment landscape for mantle cell lymphoma (MCL) is rapidly evolving, though patients with relapsed/refractory disease tend to still have poorer outcomes than others; however, hope may be on the horizon, according to Luhua (Michael) Wang, MD.

Implementation of a referral tool designed to enhance family history screening during doctor’s visits may play a crucial role in identifying those at risk for cancer.

The FDA granted a fast track designation to momelotinib for the treatment of patients with intermediate/high-risk myelofibrosis who have previously received a JAK inhibitor.

Venetoclax (Venclexta) to obinutuzumab (Gazyva) reduced the risk for disease worsening or death

Maintenance therapy with olaparib (Lynparza) significantly improved progression-free survival (PFS) compared with placebo among patients with germline BRCA-mutated metastatic pancreatic cancer, according to results from the phase III POLO trial presented at the 2019 ASCO Annual Meeting.

The FDA granted a priority review to daratumumab (Darzalex) in combination with bortezomib (Velcade), thalidomide and dexamethasone (Vtd) for the front-line treatment of newly diagnosed patients with multiple myeloma who are candidates for autologous stem cell transplant.

Two new urine tests currently being investigated for bladder cancer detection and monitoring have demonstrated more than 90% sensitivity and specificity – highlighting the potential for addressing an unmet need among this patient population.

Lenalidomide (Revlimid) significantly reduced the risk for smoldering multiple myeloma to progress to cancer among patients with moderate to high risk, according to findings from the phase II/III E3A06 trial to be presented at the 2019 ASCO Annual Meeting.

The FDA approved the combination use of avelumab plus axitinib for the first-line treatment of patients with advanced renal cell carcinoma.

Children with severe sensorineural hearing loss (SNHL) from brain tumor treatment demonstrated greater reading difficulties compared with those who experienced mild or no hearing loss.

Healthcare providers of all disciplines should work together to educate individuals about the symptoms of colorectal cancer.

In the middle of the night in June 2015, David Yoskowitz’s experience woke him with a groundbreaking idea: a cold mouthpiece that would combat chemotherapy-associated mouth sores.

Nurses play a key role in the multidisciplinary approach that is needed to care for patients with neuroendocrine tumors (NETs).

Nurses play a key role in helping to manage the chronic adverse events (AEs) associated with radiation, even into survivorship, according to Hilda Haynes-Lewis, PhD, ANP-BC, AOCNP.

Diabetes may be a risk factor for increased symptoms among breast cancer survivors, highlighting the need for interventions to control the disease, according to secondary analysis results presented at the ONS 44th Annual Congress.

Researchers found that shared decision-making as part of a pain management plan of care could improve outcomes in patients with cancer.

Researchers found significant gender and role differences regarding cardiovascular disease incidence and its related health behaviors among cancer survivors and their spouses.

Nurses can help manage post-traumatic stress disorder symptoms in survivors of non-muscle invasive bladder cancer.

Despite increased physical activity, nutritional intake behavior among female cancer survivors did not improve with an exercise intervention program, according to a randomized, controlled trial.

Nurses play a key role in nurses can play in raising awareness and educating others about a disease that is often not talked about.

Ninety percent of patients with cancer enter their first oncology appointment with a nutritional issue, according to Susan Bratton. However, Savor Health, who works in conjunctions with Merck’s Your Cancer Game Plan, has set out to combat just that.

The FDA approved the VENTANA PD-L1 (SP142) Assay as the first companion diagnostic to aid in identifying patients with triple-negative breast cancer who are eligible for treatment with Tecentriq (atezolizumab) plus chemotherapy.

Rivaroxaban (Xarelto) significantly lowered the incidence of venous thromboembolism (VTE) or death due to VTE during the intervention period with the agent in patients with solid tumors or lymphoma, according to results from the CASSINI trial.

A liquid biopsy test detected all of the guideline-recommended biomarkers in newly diagnosed patients with metastatic non-small cell lung cancer at a similar rate but faster turnaround time to that of tissue genotyping.

The FDA granted a priority review to ivosidenib (Tibsovo) for the treatment of patients with newly diagnosed acute myeloid leukemia (AML) with an IDH1 mutation who are not eligible for standard therapy.

The FDA granted a priority review to polatuzumab vedotin in combination with bendamustine plus rituximab (Rituxan) for the treatment of patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

The FDA granted a priority review to entrectinib for the treatment of adult and pediatric patients with NTRK fusion-positive, locally advanced or metastatic solid tumors and for metastatic, ROS1-positive non-small cell lung cancer.